WO1997037651A1 - Procede de preparation d'un medicament (trecresan) ayant une action nootrope - Google Patents
Procede de preparation d'un medicament (trecresan) ayant une action nootrope Download PDFInfo
- Publication number
- WO1997037651A1 WO1997037651A1 PCT/RU1996/000153 RU9600153W WO9737651A1 WO 1997037651 A1 WO1997037651 A1 WO 1997037651A1 RU 9600153 W RU9600153 W RU 9600153W WO 9737651 A1 WO9737651 A1 WO 9737651A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- mixing
- ορτο
- τρeκρezana
- drying
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 229940079593 drug Drugs 0.000 title abstract description 8
- 230000001777 nootropic effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 239000003245 coal Substances 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 5
- 238000001035 drying Methods 0.000 abstract description 5
- YUXPJMWDDQCARU-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;2-(2-methylphenoxy)acetic acid Chemical compound OCCN(CCO)CCO.CC1=CC=CC=C1OCC(O)=O YUXPJMWDDQCARU-UHFFFAOYSA-N 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- ZUBZATZOEPUUQF-UHFFFAOYSA-N isopropylhexane Natural products CCCCCCC(C)C ZUBZATZOEPUUQF-UHFFFAOYSA-N 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000002798 polar solvent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 241000490050 Eleutherococcus Species 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- DVAIYSZTXVOUQZ-UHFFFAOYSA-N diucifon Chemical compound N1C(=O)NC(=O)C(S(=O)(=O)NC=2C=CC(=CC=2)S(=O)(=O)C=2C=CC(NS(=O)(=O)C=3C(NC(=O)NC=3C)=O)=CC=2)=C1C DVAIYSZTXVOUQZ-UHFFFAOYSA-N 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- QKGYJVXSKCDGOK-UHFFFAOYSA-N hexane;propan-2-ol Chemical compound CC(C)O.CCCCCC QKGYJVXSKCDGOK-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
Definitions
- the invention is related to the field of medicine, medicine, and specifically for the treatment of medical devices, ⁇ . not affecting the human immune system and having an anti-oxidative effect [1].
- Such materials are also referred to as “immunoactive” and “immunoactive”, as long as they are of great importance. up to 40 million people in our country need it.
- osteo-oxoacetate consists in the mixture of t-iethanolamine and oupus-transcensus ⁇ ⁇ 97/37651 ⁇ / ⁇ 96 / 00153
- krezacin Obtained by the indicated method of krezacin, it has a high biological activity.
- the odorless krezacin is used in medicine by the name
- the other purpose of the invention is to increase the safety of the product and to reduce the cost of the product, the stated purpose is to be avoided by the service provider
- Heating the mixture leads to a lower temperature compared to the known solution of the temperature in the range of (45 -65] C, and cooling in the range of (5-15) "C
- Hexane may have been replaced by hetan or fuel, which is flammable and the same temperature
- thermocyanine is crystallized from isopropyl alcohol-hexane taken from the mixture.
- D ⁇ lni ⁇ eln ⁇ e improvement ⁇ aches ⁇ va ⁇ e ⁇ ezana ⁇ bes ⁇ echivae ⁇ sya ⁇ edva ⁇ i ⁇ eln ⁇ y ⁇ chis ⁇ y ⁇ - ⁇ ez ⁇ siu ⁇ susn ⁇ y ⁇ isl ⁇ y ⁇ a ⁇ zhe ⁇ u ⁇ em its mixing with coal a ⁇ ivi ⁇ vannym ma ⁇ i ⁇ G-3 P ⁇ i e ⁇ m is ⁇ lzuyu ⁇ ⁇ isanny above ⁇ same ⁇ i ⁇ ⁇ lby in ⁇ uyu zalivayu ⁇ v ⁇ dny ⁇ as ⁇ v ⁇ iz ⁇ il ⁇ v ⁇ g ⁇ s ⁇ i ⁇ a (2.4 L and 0.6 L s ⁇ i ⁇ a v ⁇ dy) of ⁇ asche ⁇ a 1 ⁇ g ⁇ isl ⁇ y 3 l v ⁇ dn ⁇ g ⁇ ⁇ as ⁇ v ⁇ a s ⁇ i ⁇ a Zag ⁇ uzhayu ⁇ 0.28 ⁇ g
- Example 1 The use of
- ECC ischemic heart disease
- For diagn ⁇ s ⁇ i ⁇ i is ⁇ lz ⁇ vali data e ⁇ a ⁇ di ⁇ g ⁇ a ⁇ ii, ⁇ e ⁇ a ⁇ lya ⁇ n ⁇ y g ⁇ udn ⁇ y ⁇ e ⁇ g ⁇ a ⁇ ii ⁇ lya ⁇ g ⁇ a ⁇ ii ⁇ ,
- Treatment was carried out by administering a dose of 0, 3 g of trekrezan (0.1 g of 3 times per day) daily for a period of three weeks (20-21 days).
- Anth-antigen 16 87 + 0, 01%.
- a traditional method was a significant increase, compared with a group of women, which was a decrease of 11%, an increase of 2.3%, + 2 + 13%, 2 + 13%, 2 + 13% 6.8 + 2 selfish2%, early infection from 7.69% up to 3.7%
- ⁇ yb ⁇ any ⁇ i g ⁇ u ⁇ y zhiv ⁇ ny ⁇ e ⁇ vaya g ⁇ u ⁇ a- ⁇ liniches ⁇ i zd ⁇ vye ma ⁇ a ⁇ i (12 ⁇ s ⁇ bey) v ⁇ aya g ⁇ u ⁇ a- ⁇ slablennye with phenomena gi ⁇ dinamii and leg ⁇ g ⁇ is ⁇ scheniya and anemia (4 ⁇ aviana) ⁇ e ⁇ ya g ⁇ u ⁇ a, ⁇ luchavshie mi ⁇ d ⁇ zu (0.1 mg / ⁇ g) a ⁇ la ⁇ sina ⁇ ( ⁇ ) (2 macaques and 1 pavian), used 5% of the injected product for injection and intramuscularly from the calculation (3-5-10 ⁇ mg / kg weight during the course of injection (1-4 1 weeks).
- G-Gluten is restored, G-Gluten is oxidized,
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Cette invention concerne essentiellement la production d'un médicament ayant des propriétés nootropes, c'est à dire agissant sur le système immunitaire humain, cette production comprenant également la purification d'une préparation connue, la Crésacine (Trécrésan). Ce procédé de production comprend les étapes suivantes: mélanger du triéthanolamine avec de l'acide ortho-crésoxyacétique dans un milieu solvant polaire et en présence de carbone actif; effectuer un premier séchage du produit obtenu avant de le recristalliser à partir d'un mélange d'alcool isopropyle et d'hexane dans une proportion de 1:1; rincer le produit à l'éther; et, enfin, effectuer un second séchage. Ce procédé concerne également la purification préliminaire de l'acide ortho-crésoxyacétique, laquelle comprend les étapes suivantes: mélanger l'acide à une solution aqueuse d'alcool en présence de carbone actif; soumettre la masse de réaction obtenue à un filtrage thermique; et enfin, filtrer et séparer les cristaux précipités avant de les rincer et de les sécher.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU61420/96A AU6142096A (en) | 1996-04-10 | 1996-06-06 | Method for producing a drug (trecresan) with nootropic activity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU96106916 | 1996-04-10 | ||
| RU96106916/14A RU2098088C1 (ru) | 1996-04-10 | 1996-04-10 | Способ получения лекарственного средства (трекрезана) с иммунотропным действием |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997037651A1 true WO1997037651A1 (fr) | 1997-10-16 |
Family
ID=20179127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU1996/000153 WO1997037651A1 (fr) | 1996-04-10 | 1996-06-06 | Procede de preparation d'un medicament (trecresan) ayant une action nootrope |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU6142096A (fr) |
| RU (1) | RU2098088C1 (fr) |
| WO (1) | WO1997037651A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2429833C1 (ru) * | 2010-09-08 | 2011-09-27 | Максуд Мухамеджанович Расулов | Средство, повышающее активность кислой липазы тромбоцитов |
| RU2486894C1 (ru) * | 2012-05-11 | 2013-07-10 | Максуд Мухамеджанович Расулов | Средство, повышающее уровень лактоферрина в организме |
| RU2486895C1 (ru) * | 2012-05-11 | 2013-07-10 | Максуд Мухамеджанович Расулов | Средство, модулирующее концентрацию ферритина в сыворотке крови |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2197962C2 (ru) * | 2000-08-28 | 2003-02-10 | Иркутская государственная сельскохозяйственная академия | Лекарственное средство для лечения железодефицитной анемии |
| RU2195936C2 (ru) * | 2000-11-17 | 2003-01-10 | Щекина Ирина Анатольевна | Способ защиты печени от ксенобиотиков в эксперименте |
| RU2224512C1 (ru) * | 2003-03-27 | 2004-02-27 | Лимонов Виктор Львович | Иммуномодулятор |
| RU2245142C1 (ru) * | 2003-07-14 | 2005-01-27 | Лимонов Виктор Львович | Иммуномодулятор |
| RU2253445C1 (ru) * | 2003-12-02 | 2005-06-10 | Лимонов Виктор Львович | Иммуномодулятор |
| RU2253444C1 (ru) * | 2003-12-02 | 2005-06-10 | Лимонов Виктор Львович | Иммуномодулятор |
| RU2268879C1 (ru) * | 2004-05-12 | 2006-01-27 | Анатолий Александрович Ермаков | Способ получения трис-(2-оксиэтил)аммоний-о-крезоксиацетата |
| RU2407526C1 (ru) * | 2009-07-27 | 2010-12-27 | Максуд Мухамеджанович Расулов | СРЕДСТВО, ПОВЫШАЮЩЕЕ АКТИВНОСТЬ СУММАРНОЙ ТРИПТОФАНИЛ-тPHK-СИНТЕТАЗЫ |
| RU2429832C1 (ru) * | 2010-04-01 | 2011-09-27 | Максуд Мухамеджанович Расулов | Применение трекрезана для лечения больных артериальной гипертонией и ожирением |
| RU2444357C1 (ru) * | 2010-12-22 | 2012-03-10 | Максуд Мухамеджанович Расулов | Средство, снижающее активность холестеролэстеразы |
| RU2445087C1 (ru) * | 2010-12-22 | 2012-03-20 | Максуд Мухамеджанович Расулов | Средство, модулирующее активность кислой фосфолипазы а1 |
| RU2564114C1 (ru) * | 2014-05-22 | 2015-09-27 | Общество с ограниченной ответственностью "Фарматрикс" (ООО "Фарматрикс") | Индуктор il-12 и il-1a |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2432392A1 (de) * | 1973-07-05 | 1975-01-30 | Ir I Orch Chimii Sib Otdel Aka | Tris-(2-hydroxyaethyl)-ammonium-orthokresoxyazetat und verfahren zu dessen herstellung |
| US4283419A (en) * | 1978-11-01 | 1981-08-11 | Voronkov Mikhail G | Preparation for raising the fertility of animals |
| AU519263B2 (en) * | 1978-11-09 | 1981-11-19 | Irkutsky Ioksoans | Preparation for rasing fertility in animals |
-
1996
- 1996-04-10 RU RU96106916/14A patent/RU2098088C1/ru not_active IP Right Cessation
- 1996-06-06 AU AU61420/96A patent/AU6142096A/en not_active Abandoned
- 1996-06-06 WO PCT/RU1996/000153 patent/WO1997037651A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2432392A1 (de) * | 1973-07-05 | 1975-01-30 | Ir I Orch Chimii Sib Otdel Aka | Tris-(2-hydroxyaethyl)-ammonium-orthokresoxyazetat und verfahren zu dessen herstellung |
| FR2235681A1 (fr) * | 1973-07-05 | 1975-01-31 | Ir I Orch | |
| US4283419A (en) * | 1978-11-01 | 1981-08-11 | Voronkov Mikhail G | Preparation for raising the fertility of animals |
| AU519263B2 (en) * | 1978-11-09 | 1981-11-19 | Irkutsky Ioksoans | Preparation for rasing fertility in animals |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2429833C1 (ru) * | 2010-09-08 | 2011-09-27 | Максуд Мухамеджанович Расулов | Средство, повышающее активность кислой липазы тромбоцитов |
| RU2486894C1 (ru) * | 2012-05-11 | 2013-07-10 | Максуд Мухамеджанович Расулов | Средство, повышающее уровень лактоферрина в организме |
| RU2486895C1 (ru) * | 2012-05-11 | 2013-07-10 | Максуд Мухамеджанович Расулов | Средство, модулирующее концентрацию ферритина в сыворотке крови |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2098088C1 (ru) | 1997-12-10 |
| AU6142096A (en) | 1997-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997037651A1 (fr) | Procede de preparation d'un medicament (trecresan) ayant une action nootrope | |
| Khory et al. | Materica Medica of India and Their Therapeutics | |
| KR100189144B1 (ko) | 신규 생리 활성 물질 | |
| US10265345B2 (en) | Use of extracts from rabbit skin inflamed by vaccinia virus for the manufacture of a medicament for the treatment of acute cerebrovascular disease | |
| EP1752155A4 (fr) | Compositions de correction de changements du systeme endocrinien humain dus a l'age et procede de fabrication d'une forme pharmaceutique sur la base de ces compositions | |
| CN111820314A (zh) | 一种利用鹿血多肽和枸杞多糖制备的抗疲劳保健品 | |
| WO2007071334A2 (fr) | Extraits de phaseolus vulgaris, leur utilisation, et préparations les contenant | |
| DE3319575A1 (de) | Therapeutisch wirksame zusammensetzungen, nahrungsmittel und getraenke | |
| EP1757299A1 (fr) | Complexes de fer III pour traiter les manques de fer en patients avec la maladie intestinale inflammatoire | |
| WO2003072124A1 (fr) | Methode d'induction de differentiation cellulaire | |
| BRODIE et al. | Acute hepatic porphyrias | |
| CN101633945A (zh) | 一种含vvyp肽的珠肽粉的制备方法 | |
| JP2010100530A (ja) | 抗肥満剤 | |
| JPH07285881A (ja) | アルコール代謝促進剤 | |
| RU2377005C1 (ru) | Способ лечения желудочно-кишечных болезней у телят | |
| DE60037197T2 (de) | Verwendung funktioneller oraler präparate | |
| WO2004064849A1 (fr) | Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale | |
| RU2086244C1 (ru) | Способ приготовления препарата для животных из растительного или животного сырья | |
| US6884421B2 (en) | Pharmaceutical composition for diabetic nephropathy | |
| WO2002043740A1 (fr) | Procede de fabrication d'un produit antiviral immunotropique | |
| WO2002092110A1 (fr) | Nouvelle utilisation de polyphenol de plantes naturelles et de medicaments et/ou de produits medicaux contenant du polyphenol de plantes naturelles | |
| WO1997045530A1 (fr) | Utilisation de souches de streptococcus faecium et composition a base de ces souches | |
| CN117338869B (zh) | 一种用于治疗便秘和改善皮肤暗沉的中药胶囊及其制备方法 | |
| JP3764496B2 (ja) | アルコール性肝機能障害抑制剤 | |
| US3020204A (en) | Process for preparing augmentative intrinsic factor concentrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97536105 Format of ref document f/p: F |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |